The mission of the Neuro-Oncology Division is to advance knowledge related to the etiology and biology of brain tumors in children, to provide optimal treatment and work towards cures for these diseases. The division strives to provide unsurpassed medical care and to conduct internationally recognized clinical and translational research.
The Neuro-Oncology Division is an integral part of the larger institutional Brain Tumor Program, which is a multidisciplinary team representing pediatric oncology, neuro-oncology, neurosurgery, radiation oncology, neuroradiology, pathology and neuropsychology. The focus of the program is on innovative therapeutic interventions, including new chemotherapeutic agents studied in conjunction with internationally recognized laboratories in clinical pharmacology and molecular biology. Clinical trials are developed within the institution and in collaboration with other strong pediatric neuro-oncology programs, cooperative groups and the Pediatric Brain Tumor Consortium. The program is one of the largest clinical brain tumor programs in North America and currently sees a large number of new patients per year in addition to a similar number of consults from other institutions. Novel institutional studies are currently ongoing in infant CNS tumors, medulloblastoma, malignant gliomas and localized, low grade neoplasms. Additionally, the program has developed an active long term follow-up effort that helps identify, treat and study the late sequelae of disease and treatment for childhood brain tumors.
Division of Neuro-Oncology
MS 260, Room C6024
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Phone: (901) 595-2615
Fax: (901) 595-6211
Preferred contact method: email
Pediatric neuro-oncology and cancer survivorship
Biology and treatment of high-grade gliomas
Novel treatments for children with brain tumors
Low grade gliomas, global health, telemedicine and retinoblastoma
Origin and genomics of medulloblastoma, translational studies
Infant medulloblastoma, high grade glioma in young children